AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-134731518/business-briefs-point.html" title="Facts and information about BUSINESS BRIEFS.(TO THE POINT)">BUSINESS BRIEFS.(TO THE POINT)</a>
Close
Set up an RSS feed that alerts you when new articles from Investor's Business Daily are available.
Frequently asked questions about RSS feeds
BUSINESS BRIEFS.(TO THE POINT)
MEDICAL
Teva Q2 profit up, light on sales
The Israeli generic drug maker met views for a 6% rise to 36 cents a share. Sales rose 4% to $1.23 bil, a bit shy. MS drug Copaxone's 29% rise in global sales to $291 mil helped offset an 8% slide in U.S. drug sales to $624 mil. Teva has agreed to buy ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Guidant Updates Corrective Actions Regarding Its VENTAK PRIZM AVT, VITALITY...
- Press release article from: Business Wire July 22, 2005 700+ words
...NYSE:GDT) said today it is updating previous safety information regarding its VENTAK PRIZM AVT, VITALITY AVT, and CONTAK RENEWAL AVT devices. FDA may consider this action a recall. This update revises the original recommendations set forth in Guidant...
- Guidant (Indianapolis, Indiana) continued its recent rapid pace of approvals in...
- Newspaper article from: Cardiovascular Device Update February 1, 2003 700+ words
...recent rapid pace of approvals in the congestive heart failure (CHF) arena with the mid-January FDA clearance of the Contak Renewal cardiac resynchronization therapy defibrillator (CRT-D). The company said full commercial launch of the advanced heart...
- FDA ok.(Friday, March 2)(Food and Drug Administration)(Procleix Tigris...
- Magazine article from: San Diego Business Journal Weeks, Katie March 12, 2007 700+ words
FDA OK: Gen-Probe Inc. announced the Food and Drug Administration has approved the San Diego-based company's device to test donated...
- Pfizers FDA OK To Begin Glaucoma Drug Candidate Study, Triggers Payment To...
- News wire article from: The America's Intelligence Wire March 29, 2007 700+ words
(From FinancialWire) Byline: DAVID WEBER FinancialWire-29 March 2007-Pfizers FDA OK To Begin Glaucoma Drug Candidate Study, Triggers Payment To NicOx (C)2007 Investrend Communications, Inc. March 29, 2007...
- FDA OK.(United States. Food and Drug Administration)(Brief article)
- Magazine article from: San Diego Business Journal Weeks, Katie September 4, 2006 700+ words
FDA OK: San Diego's DexCom Inc. received approval from the Food and Drug Administration for a software program used to help diabetes patients manage glucose levels.
- Bio-Data gets FDA ok to market product. (Bio-Data Corp.) (product announcement)
- Magazine article from: Philadelphia Business Journal Reichert, Kent December 14, 1987 700+ words
Bio/Data gets FDA OK to market product Hatboro-based Bio/Data Corp. has received clearance from the Food and Drug Administration (FDA) to market...
- Dr. Reddys Gets FDA OK For Generic Famotidine 20 MG.
- News wire article from: The America's Intelligence Wire September 28, 2006 700+ words
(From FinancialWire) FinancialWire-28 September 2006-Dr. Reddys Gets FDA OK For Generic Famotidine 20 MG (C)2006 Investrend Communications, Inc. September 28, 2006 (FinancialWire) Leiner Health Products...
- GW Medical, assuming FDA OK, set to market 1st AD blood test.
- Magazine article from: Medical Device Week April 8, 2005 700+ words
GW Medical, assuming FDA OK, set to market 1st AD blood test By KAREN YOUNG Medical Device Daily Staff Writer If all goes as planned, GW Medical Technologies...
- Amplatzer device gets FDA OK to close VSD holes in the heart.
- Magazine article from: Medical Device Week September 12, 2007 700+ words
Amplatzer device gets FDA OK to close VSD holes in the heart By OMAR FORD Medical Device Daily Staff Writer Look at the facts. Any physician will quickly point...
- Merck Has Hopes for Arcoxia, But FDA OK May Not Be Among Them.
- News wire article from: The America's Intelligence Wire October 20, 2004 700+ words
(From FinancialWire) FinancialWire-20 October 2004-Merck Has Hopes for Arcoxia, But FDA OK May Not Be Among Them (C)2004 Investrend Communications, Inc. October 20, 2004. (FinancialWire) Mercks (NYSE: MRK...